MEG3-lncRNA expression has been suggested as a potential biomarker for therapy response and survival profile in childhood acute lymphoblastic leukemia (cALL) [41], whereas encompasses miRNAs and promoter regions of miRNA species (Table 3). This evidence concerns the gene MEG3 and acute lymphoblastic leukemia.